An increasing portion of biomedical research relies on the use of biobanks and databases. Sharing of such resources is essential for optimizing knowledge production. A major obstacle for sharing bioresources is the lack of recognition for the efforts invol

We present the discovery, classification, and extensive panchromatic (from radio to X-ray) follow-up observations of PTF11qcj, a supernova (SN) discovered by the Palomar Transient Factory (PTF). Our observations with the Karl G. Jansky Very Large Array show that this event is radio-loud: PTF11qcj reached a radio peak luminosity comparable to that of the famous gamma-ray-burst-associated SN 1998bw (L 5 GHz 1029 erg s-1 Hz-1). PTF11qcj is also detected in X-rays with the Chandra Observatory, and in the infrared band with Spitzer. Our multi-wavelength analysis probes the SN interaction with circumstellar material. The radio observations suggest a progenitor mass-loss rate of 10-4 M yr-1 × (vw /1000 km s-1), and a velocity of 0.3-0.5 c for the fastest moving ejecta (at 10 days after explosion). However, these estimates are derived assuming the simplest model of SN ejecta interacting with a smooth circumstellar wind, and do not account for possible inhomogeneities in the medium and asphericity of the explosion. The radio data show deviations from such a simple model, as well as a late-time re-brightening. The X-ray flux from PTF11qcj is compatible with the high-frequency extrapolation of the radio synchrotron emission (within the large uncertainties). A light echo from pre-existing dust is in agreement with our infrared data. Our pre-explosion data from the PTF suggest that a precursor eruption of absolute magnitude Mr -13 mag may have occurred 2.5 yr prior to the SN explosion. Overall, PTF11qcj fits the expectations from the explosion of a Wolf-Rayet star. Precursor eruptions may be a feature characterizing the final pre-explosion evolution of such stars. © 2014. The American Astronomical Society. All rights reserved..

Background

The erosion of the early mortality advantage of elective endovascular aneurysm repair (EVAR) compared with open repair of abdominal aortic aneurysm remains without a satisfactory explanation.

Methods

An individual-patient data meta-analysis of four multicentre randomized trials of EVAR versus open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related mortality and reintervention.

Results

The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5·5 years). Early (0-6 months after randomization) mortality was lower in the EVAR groups (46 of 1393 versus 73 of 1390 deaths; pooled hazard ratio 0·61, 95 per cent c.i. 0·42 to 0·89; P = 0·010), primarily because 30-day operative mortality was lower in the EVAR groups (16 deaths versus 40 for open repair; pooled odds ratio 0·40, 95 per cent c.i. 0·22 to 0·74). Later (within 3 years) the survival curves converged, remaining converged to 8 years. Beyond 3 years, aneurysm-related mortality was significantly higher in the EVAR groups (19 deaths versus 3 for open repair; pooled hazard ratio 5·16, 1·49 to 17·89; P = 0·010). Patients with moderate renal dysfunction or previous coronary artery disease had no early survival advantage under EVAR. Those with peripheral artery disease had lower mortality under open repair (39 deaths versus 62 for EVAR; P = 0·022) in the period from 6 months to 4 years after randomization.

Conclusion

The early survival advantage in the EVAR group, and its subsequent erosion, were confirmed. Over 5 years, patients of marginal fitness had no early survival advantage from EVAR compared with open repair. Aneurysm-related mortality and patients with low ankle : brachial pressure index contributed to the erosion of the early survival advantage for the EVAR group. Trial registration numbers: EVAR-1, ISRCTN55703451; DREAM (Dutch Randomized Endovascular Aneurysm Management), NCT00421330; ACE (Anévrysme de l'aorte abdominale, Chirurgie versus Endoprothèse), NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), NCT00094575.